drugset
drugset / Trial / NCT04830345

Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines

NCT04830345 ↗

Phase 3 Completed 290 enrolled EuBiologics Co.,Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.

Timeline

Start
2020-06-29
Primary completion
2021-09-01
Completion
2021-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ATGC-100 Unknown 100 iu Other
Comparator Botulinum toxin type A Protein / enzyme biologic 100 iu Other

Indications

No indication recorded.